Antibody-Drug Conjugates – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Antibody-drug conjugates (ADCs) are a cutting-edge class of biopharmaceutical drugs that combine monoclonal antibodies (mABs) with cytotoxic drugs for targeted therapy. Analysis of patents, patent trends, and related literature indicates that ADCs are a highly impactful innovation in the medium-term. This innovation is primarily driven by major pharmaceutical companies, which account for 37% of all patents. The commercial impact is evident from a robust drug pipeline, recent global drug approvals, and various investment activities such as mergers and acquisitions, corporate venture funding, and licensing agreements.
Patenting trends experienced a significant increase in 2017 and have continued to grow since then. While oncology remains the dominant indication, there is a noticeable rise in new therapy areas such as autoimmune diseases and infectious diseases, potentially leading to the entry of new players into the market. The United States remains the leading geography for ADC innovation, closely followed by China.
The innovation landscape is highly competitive, with over 100 public companies identified. Leading patent filers include Roche, Seagen (Pfizer), AstraZeneca, and Abbvie. Among big pharma companies, Daiichi Sankyo, AstraZeneca, and Abbvie have the strongest patent portfolios. In China, Jiangsu Hengrui, Biocytogen, and GeneQuantum lead among the 30+ companies in the space.
There are over 70 startups and small biotech companies in the ADC space, with nearly a quarter of them based in China. GeneQuantum, Oncomatryx, Glykos, and DAC Biotech are leading in terms of patent volumes among startups.
The Antibody Drug Conjugate drug landscape includes 1,172 drugs, primarily focused on oncology (94%) and immunology (1.8%) therapies. The most common route of administration is intravenous. Companies like Biocytogen Pharmaceuticals (Beijing) Co Ltd and Hangzhou DAC Biotech Co Ltd are at the forefront of drug development, particularly in preclinical and Phase II trials. The concentration of drugs in Phase I and Phase II suggests a maturing pipeline with potential market entry in the near future.
There have been 2,847 clinical trials for Antibody Drug Conjugate drugs, with Pfizer and Daiichi Sankyo leading as top sponsors. Oncology trials dominate, with Hodgkin Lymphoma being the top indication. In terms of deals, there have been 809 deals totaling US$227 billion, with the United States leading in both deal volume and value. The market saw a decline in deals from 2020-2022, followed by a slight increase in 2023, indicating market adjustments and strategic consolidations.

Scope

Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.

Key player: This represents a sample list of key players in each use case highlighted in the report.

Startups: This represents a sample list of emerging starups in each use case highlighted in the report.

University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

1. Antibody Drug Conjugate report is a high-impact innovation area in the Pharma industry, with a growing number of patents being filed and a focus on new indications such as Oncology and Autoimmune Diseases.

2. Big pharma companies like Roche dominate the patent activity in Antibody Drug Conjugate with a dip in new companies filing patents in recent years.

3. Competitive intelligence shows that Merck and seagen in terms of portfolio size are among the leaders with strong innovation portfolios in Antibody Drug Conjugate.

4. The drug landscape for Antibody Drug Conjugate is dominated by innovator drugs, with a focus on Infectious Disease and Immunology, and major players like Biocytogen Pharma and Hangzhou Biotech leading in drug development.

5. Clinical trials in Antibody Drug Conjugate are dominated by Immunology trials, with the Pfizer Inc and Daiichi Sankyo Ltd leading in the number of trials.

Reasons to Buy

Accelerate Innovation with Our Antibody-Drug Conjugates Report:

Emerging technologies like antibody-drug conjugates (ADCs) are transforming the biotech and pharmaceutical landscape. Our comprehensive report delivers critical insights into the latest research, patents, clinical trials, and market trends, empowering strategic decision-making. Gain a competitive edge with data on leading pharma companies, startups, and academic institutions, helping you identify growth opportunities and potential threats. The report also highlights regulatory and compliance developments, essential for navigating complex healthcare frameworks. Whether optimizing R&D strategies or uncovering market opportunities, this report is an invaluable resource for making informed, data-driven decisions in today’s fast-evolving therapeutic landscape

Biocytogen Pharmaceuticals (Beijing) Co Ltd
Hangzhou DAC Biotech Co Ltd
LigaChem Biosciences Inc
Pfizer Inc
Genmab AS
Cidara Therapeutics Inc
Duality Biologics (Shanghai) Co Ltd
Shanghai Affinity Biopharmaceutical Co Ltd
AstraZeneca Plc
Immunome Inc
AbTis Co Ltd
iProgen Biotech Inc
Suzhou Medilink Therapeutics Ltd
Jiangsu Hengrui Medicine Co Ltd
Innovent Biologics Inc
ADC Therapeutics SA
AbbVie Inc
Hangzhou Adcoris Biopharmaceutical Co Ltd
LaNova Medicines Ltd
GeneQuantum Healthcare Suzhou Co Ltd
Alphamab Oncology
Exelixis Inc
Merck KGaA
Mersana Therapeutics Inc
Zymeworks Inc
Xiling Lab Co Ltd
Intocell Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
MabGen Biotech Co Ltd
SOTIO Biotech AS
BiOneCure Therapeutics Inc
Daiichi Sankyo Co Ltd
Multitude therapeutics Inc
Iksuda Therapeutics Ltd
Bio-Thera Solutions Ltd
Oxford BioTherapeutics Ltd
Sichuan Biokin Pharmaceutical Co Ltd
Byondis BV
Actinium Pharmaceuticals Inc
Catalent Inc
Shanghai Miracogen Inc
Antikor Biopharma Ltd
Telix Pharmaceuticals Ltd
OBI Pharma Inc
Bayer AG
Debiopharm International SA
Tagworks Pharmaceuticals BV
Eli Lilly and Co
Adcentrx Therapeutics Inc
Genentech USA Inc.

Table of Contents

Table of Contents

1. Innovation Insights

1.1 Innovation radar

1.2 Innovation s-curve

1.3 Innovation deep dive

1.4 Innovation deep dive – trending indications

1.5 Top companies Based on portfolio strength and temporal indicators

2. Competitive Insights

2.1 Key innovation leaders – big pharma

2.2.Key innovators – startups and small biotech

2.3 Key innovations – Universities and research institutions

2.4 Most cited patents

2.5 Insights from AI hub

3.Market Insights

3.1 Drugs

3.1.1 Key Players

3.1.2 Route of administration & drug type

3.1.3 Top therapy area & indication

3.2 Clinical Trials

3.2.1 Key Sponsors

3.2.2 Key development stages

3.3 Deals

3.3.1. Key Acquirers

3.3.2 Deal type distribution

3.3.3 Geographical distribution

Antibody-Drug Conjugates – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals standard reports
Currency USD
$2,499

Can be used by individual purchaser only

$7,497

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Antibody-Drug Conjugates – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Antibody-Drug Conjugates – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals in real time.

  • Access a live Antibody-Drug Conjugates – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.